Back to Search
CORA RYAN, PH.D., HSP-P
PH.D., HSP-P
Psychologist
NPI: 1467029249Individual
Specialties, Licenses & Credentials
PsychologistPrimary
Psychologist
Code: 103T00000X
5813(NC)
Research & Publications (20)
Juvenile folliculotropic and ichthyosiform mycosis fungoides.
PMID 19094122·Clin Exp Dermatol·2009
5-case
Family rejection as a predictor of negative health outcomes in white and Latino lesbian, gay, and bisexual young adults.
PMID 19117902·Pediatrics·2009
4-observational
Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
PMID 19438535·Clin Exp Dermatol·2009
8-other
A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
PMID 18234062·BJU Int·2008
8-other
Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.
PMID 18491370·Prostate·2008
8-other
The reduced local lymph node assay: the impact of group size.
PMID 17879259·J Appl Toxicol·2008
7-preclinical
Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.
PMID 18348295·Cancer·2008
3-trial
British outpatient norms for the Brief Symptom Inventory.
PMID 17535593·Psychol Psychother·2007
4-observational
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
PMID 17552955·BJU Int·2007
2-rct
Extrapolating local lymph node assay EC3 values to estimate relative sensitizing potency.
PMID 17612980·Cutan Ocul Toxicol·2007
8-other
Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial design.
PMID 17644122·J Urol·2007
6-review
Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
PMID 17656221·Urology·2007
2-rct
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
PMID 17664477·J Clin Oncol·2007
3-trial
Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE.
PMID 17516446·Cancer·2007
8-other
Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
PMID 17404083·Clin Cancer Res·2007
3-trial
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
PMID 17458505·Invest New Drugs·2007
3-trial
Dendritic cells and skin sensitization: biological roles and uses in hazard identification.
PMID 17493650·Toxicol Appl Pharmacol·2007
6-review
clinical research, innovative practice and IRB review: identifying and respecting boundaries.
PMID 17331113·Am J Transplant·2007
8-other
Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
PMID 17936834·J Urol·2007
3-trial
Androgen deprivation therapy in locally advanced and metastatic prostate cancer.
PMID 17124482·Minerva Urol Nefrol·2006
1-meta
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 233A MERCHANTS CIR STE 204
HAMPSTEAD, NC 28443 - Phone
- (910) 406-1027
Quick Facts
- NPI
- 1467029249
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile